A

Simulated % of Patients with PCR-positive samples at end of treatment

Legend:
- A – Control – Standard of care
- B – Raw data 200mg TID
- C – Raw data 200mg TID + 200mg TID + Azythromycin
- D – 800mg BID (1d) + 400mg BID (4d)
- E – 800mg BID (2d) + 400mg BID (3d)
- F – 800mg BID (3d) + 400mg BID (2d)
- G – 800mg BID (1d) + 400mg BID (6d)
- H – 800mg BID (2d) + 400mg BID (5d)
- I – 600mg BID (1d) + 200mg TID (6d)
- J – 600mg BID (2d) + 200mg TID (5d)

Hydroxychloroquine Regimen

B

Percent of patients predicted to have QTc >500ms

Hydroxychloroquine Regimen

X-axis labels: 200mg TID x 10 days; 800mg BID (1d) + 400mg BID (4d); 800mg BID (2d) + 400mg BID (3d); 800mg BID (3d) + 400mg BID (2d); 800mg BID (1d) + 400mg BID (6d); 800mg BID (2d) + 400mg BID (5d); 600mg BID (1d) + 400mg BID (6d); 600mg BID (2d) + 400mg BID (5d)

C

Percent of patients predicted to have QTc >500ms

Hydroxychloroquine Regimen

X-axis labels: 200mg TID x 10 days; 800mg BID (1d) + 400mg BID (4d); 800mg BID (2d) + 400mg BID (3d); 800mg BID (3d) + 400mg BID (2d); 800mg BID (1d) + 400mg BID (6d); 800mg BID (2d) + 400mg BID (5d); 600mg BID (1d) + 400mg BID (6d); 600mg BID (2d) + 400mg BID (5d)

Figure S4: Simulated proportion of adults with detectable viral loads at the end of treatment, stratified by regimen, when combining different loading and maintenance doses. B) Predicted percent of adults with (baseline QTc of 394 + 30SD) a QTc over 500msec for each regimen with a loading dose. C) Predicted percent of adults with (baseline QTc of 420 + 30SD) a QTc over 500msec for each regimen with a loading dose.